ENZON PHARMACEUTICALS, INC.

Inactive Instrument

Other languages Enzon Pharmaceuticals, Inc. Other OTC

Equities

ENZN

US2939041081

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/05/23
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	16/02/23
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	25/02/22
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	05/11/21
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	05/08/21
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	04/05/21
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	23/02/21
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	09/11/20
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	29/07/20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer